Professor Graham Foster

Profile

Professor Foster is the Professor of Hepatology at  Queen Mary University of London and a consultant at Barts Health Trust. He trained in Medicine at Oxford and London Universities in the 1980s and completed a PhD in Molecular Biology in 1992.  Professor Foster has a long-standing interest in the management of chronic viral hepatitis and runs a clinical research program studying the natural history of viral hepatitis, its impact upon patients and their communities and novel therapies for this disease. He supervises a laboratory research program investigating the basic virology of hepatotropic viruses novel replication models for hepatitis C. He is the editor of The Journal of Viral Hepatitis and has published widely in the field of viral liver disease. He is a past President of BASL, NHSE Clinical Lead for Hepatitis C, Chairman the NHSE Hepatolbiliary Specialised Commissioning Clinical Reference Group

Summary

Professor Foster is the Professor of Hepatology at  Queen Mary University of London and a consultant at Barts Health Trust. He trained in Medicine at Oxford and London Universities in the 1980s and completed a PhD in Molecular Biology in 1992.  Professor Foster has a long standing interest in the management of chronic viral hepatitis and runs a clinical research program studying the natural history of viral hepatitis, its impact upon patients and their communities and novel therapies for this disease. He supervises a laboratory research program investigating the basic virology of hepatotropic viruses novel replication models for hepatitis C.  He is the sub-editor of The Journal of Viral Hepatitis and has published widely in the field of viral liver disease. He is President of BASL, Vice Chairman the UK Department of Health Advisory Group on Hepatitis and a member of a number of patient advocacy groups.

Research

Research Interests:

Professor Foster leads an academic group studying the elimination of hepatitis C in England and abroad. As the national clinical lead for the NHSE Hepatitis C elimination program he is responsible for developing and assessing novel interventions that will lead to reductions in the burden of viral hepatitis. He works with international collaborators in Pakistan and Zambia studying new approaches to managing viral hepatitis and leads a group evaluating the impact of viral polymorphisms on treatment and development of liver cancer.

Publications

Key Publications

Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. Wing PAC, Jones M, Cheung M, DaSilva S, Bamford C, Jason Lee WY, Aranday-Cortes E, Da Silva Filipe A, McLauchlan J, Smith D, Irving W, Cunningham M, Ansari A, Barnes E, Foster GR. Gastroenterology. 2019 Sep;157(3):692-704.e9. doi: 10.1053/j.gastro.2019.05.007. Epub 2019 May 10. PMID: 31078622 

Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. Flanagan S, Kunkel J, Appleby V, Eldridge SE, Ismail S, Moreea S, Griffiths C, Walton R, Pitt M, Salmon A, Madurasinghe V, Barnes E, Simms E, Agarwal K, Foster GR. Lancet Gastroenterol Hepatol. 2019 Jan;4(1):32-44. doi: 10.1016/S2468-1253(18)30318-2. Epub 2018 Nov 24. PMID: 30477810 

Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. Zeuzem S*, Foster GR*, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. N Engl J Med. 2018 Jan 25;378(4):354-369. doi: 10.1056/NEJMoa1702417. PMID: 29365309 

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators. N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17. PMID: 26575258 

Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis. Alazawi W, Heath H, Waters JA, Woodfin A, O'Brien AJ, Scarzello AJ, Ma B, Lopez-Otalora Y, Jacobs M, Petts G, Goldin RD, Nourshargh S, Gamero AM, Foster GR. Proc Natl Acad Sci U S A. 2013 May 21;110(21):8656-61. doi: 10.1073/pnas.1221652110. Epub 2013 May 7. PMID: 23653476

View Professor Foster's full publications at: http://www.researchpublications.qmul.ac.uk